Phosphate Therapeutics is developing an innovative treatment for patients with Chronic Kidney Disease and who display elevated serum-phosphate levels. High phosphate levels cause numerous secondary problems and strongly correlate with worse prognosis. The drug is based on natural substances with very good safety profiles and has shown superior efficacy in early clinical studies.
Phosphate Therapeutics acquires licence and €10.5m funding for Phase 2-ready phosphate binder for treatment of hyperphosphataemia
2012-03-05
- London-based Phosphate Therapeutics has raised 10.5 million euros ($13.8 million) from Inventages Venture Capital. The money is supporting development of its PT20 drug, which is designed to treat hyperphosphataemia. The company is also backed by the Medical Research Council's Development Gap Fund, the company said.
